The study, conducted by Fei Xia and Kecheng Li of the Laboratory Department at Ruian People’s Hospital in Zhejiang province and published in BMC Infectious Diseases, followed 141 consecutive adults with laboratory-confirmed C. difficile infection admitted between January 2020 and December 2023. All patients received standard oral therapy, either metronidazole at 500 milligrams three times daily or vancomycin at 125 milligrams four times daily, and each underwent a follow-up PCR test between seven and twenty-one days after treatment began. From the paired measurements the researchers calculated ΔCt, the change in the tcdB cycle threshold between the initial diagnostic sample and the follow-up specimen. A rising Ct over time, and therefore a positive ΔCt, indicates that the bacterial toxin-gene load is falling as therapy takes hold, while a flat or negative ΔCt suggests that the organism persists at high levels despite treatment.

The cohort was strikingly elderly. The median age was 78 years, and nearly six in ten patients, 59.6 percent, were 75 or older, reflecting the population in which C. difficile infection does its greatest damage. Using the severity criteria of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America, the investigators classified 101 patients, 71.6 percent, as having non-severe disease, defined by a white blood cell count of 15,000 cells per microlitre or less and a serum creatinine below 1.5 milligrams per decilitre. The remaining 40 patients, 28.4 percent, met the criteria for severe infection because their white cell counts exceeded that threshold or their creatinine reached or surpassed 1.5 milligrams per decilitre, markers of systemic inflammation and kidney injury that have long anchored clinical severity scoring in this disease.

When the researchers compared ΔCt values across these severity categories, the separation was unmistakable. Patients with severe disease had a median ΔCt of just +0.3, with an interquartile range spanning −1.0 to +1.3, meaning that the toxin B gene signal in their follow-up samples had barely budged from baseline. Patients with non-severe disease, by contrast, showed a median ΔCt of +5.3, with an interquartile range of 3.0 to 6.6, indicating a substantial decline in detectable bacterial load. The Spearman correlation coefficient between ΔCt and severity was −0.53, with a p value below 0.001, a moderate and highly significant inverse relationship: the smaller the rise in Ct, the more likely the patient was to have severe infection. Notably, the initial Ct value itself did not differ between severity groups, with a p value of 0.486. The single snapshot of bacterial burden at diagnosis carried no severity signal; it was the trajectory, the change over the first weeks of therapy, that mattered.

Exploratory receiver operating characteristic analysis reinforced this picture. For distinguishing severe from non-severe disease, ΔCt achieved an area under the curve of 0.837, with a 95 percent confidence interval of 0.759 to 0.907, a level of discrimination that approaches the performance of established clinical scoring tools. For a laboratory marker derived from a routine diagnostic assay that is otherwise discarded, this is a remarkable result. It suggests that the quantitative output of the nucleic acid amplification test, interpreted dynamically rather than as a one-off reading, could give clinicians an early, objective readout of microbiological response, complementing white cell counts and creatinine measurements that reflect the host’s inflammatory and organ response rather than the pathogen itself.

But the story turns when the endpoint shifts from severity to outcome. Fifty patients in the cohort, 35.5 percent, experienced what the investigators defined as a poor clinical outcome: either death in hospital or discharge against medical advice, a composite that captures both the ultimate failure of treatment and the pragmatic reality that some gravely ill patients leave care before it concludes. When ΔCt was tested against this composite endpoint, the association vanished. The p value was 0.217, and the area under the curve fell to 0.563, with a confidence interval of 0.458 to 0.663, a range that straddles the 0.5 line of a coin flip. A marker that cleanly separates severe from non-severe infection, in other words, does not reliably separate those who will die or abandon treatment from those who will recover and be discharged.

To understand what actually drove poor outcomes, the team turned to multivariable logistic regression, and the answer was emphatically clinical rather than microbiological. Only two factors emerged as independent predictors. Age of 75 years or older carried an adjusted odds ratio of 8.13, with a 95 percent confidence interval of 2.45 to 27.01, meaning that the oldest patients faced roughly eightfold higher odds of a poor outcome after adjustment for other variables. Admission to the intensive care unit was even more dominant, with an adjusted odds ratio of 23.21 and a confidence interval of 7.84 to 68.66. Two other factors, receipt of three or more non-CDI antibiotics and a diagnosis of diabetes mellitus, reached significance only in univariate analysis and did not survive adjustment. The bacterial load trajectory, the very measurement that tracked severity so well, contributed nothing independent once these host factors were accounted for.

The dissociation between severity and outcome is not as paradoxical as it first appears, and it speaks to a fundamental truth about C. difficile infection in ageing hospital populations. Severity criteria such as leukocytosis and elevated creatinine describe the acute physiological storm of the infection, and a falling toxin-gene burden on repeat PCR plausibly mirrors that storm’s intensity. Death and treatment abandonment, however, are shaped by frailty, comorbidity, the trajectory of the underlying illness that brought the patient to hospital, and the accumulated burden of intensive care. An 80-year-old in the ICU may clear C. difficile toxin gene signal admirably on repeat testing and still die of the confluence of age, organ failure and critical illness. ΔCt measures the microbe’s retreat; the outcome is decided largely by the host’s reserves.

The authors are careful about what their findings do and do not license. As a retrospective, single-centre study of 141 patients treated with a limited formulary at one Chinese tertiary hospital, it cannot establish causation, and the composite outcome of in-hospital death or discharge against medical advice, while pragmatic, is heterogeneous. The follow-up PCR window of seven to twenty-one days is wide, and no consensus protocol exists for serial Ct monitoring during CDI treatment, which is precisely the gap the study set out to probe. The researchers conclude that ΔCt monitoring in this window provides clinically relevant information on microbiological response and disease severity but does not independently predict clinical outcomes, and they call for prospective validation using predefined, outcome-based endpoints before any ΔCt-based monitoring strategy enters routine practice.

Even so, the study gestures toward a quietly practical shift. The Ct value is already generated every time a molecular C. difficile test runs; capturing it, archiving it, and comparing it across serial samples costs nothing beyond a change in laboratory habit and reporting. If larger prospective studies confirm that a sluggish rise in Ct flags severe disease early, clinicians could gain a cheap, objective adjunct for triaging which patients need intensified monitoring, escalation to vancomycin or fidaxomicin, or closer surveillance for complications, while reserving prognostic weight for the factors that truly drive outcomes: advanced age and critical illness. For now, the discarded number has earned a second look, but not the final word.

Subject of Research: Serial PCR cycle threshold dynamics of the tcdB gene as a marker of disease severity and outcome in hospitalized patients with Clostridioides difficile infection

Article Title: Serial ΔCt (tcdB) dynamics as a correlate of disease severity but not an independent predictor of poor outcome in hospitalized patients with clostridioides difficile infection: a retrospective cohort study

Article References: Xia, F., & Li, K. (2026). Serial ΔCt (tcdB) dynamics as a correlate of disease severity but not an independent predictor of poor outcome in hospitalized patients with clostridioides difficile infection: a retrospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14609-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14609-4

Keywords: Clostridioides difficile, PCR cycle threshold, tcdB, delta Ct, disease severity, clinical outcomes, retrospective cohort, hospitalized patients, IDSA/SHEA criteria, ICU admission, advanced age, diagnostics

The study team, led by Reza Zabihi of the Student Research Committee at Babol University of Medical Sciences together with colleagues from the university’s departments of internal medicine, social determinants of health, and infectious diseases research, designed the investigation as a matched-style comparison rather than a simple survey of liver patients. They enrolled 37 hospitalized COVID-19 patients with documented pre-existing chronic liver disease and selected 77 comparison patients who were hospitalized with confirmed COVID-19 but had neither chronic liver disease nor other documented chronic comorbidities. This deliberate selection of a relatively clean comparison group is analytically important: by stripping away diabetes, cardiovascular disease, and other common confounders, the researchers sought to isolate the contribution of liver pathology itself to COVID-19 outcomes, rather than the contribution of multimorbidity in general.

The demographic profiles of the two groups were closely aligned. The mean age in the chronic liver disease group was 57.03 years with a standard deviation of 13.85, while the comparison group averaged 55.05 years with a standard deviation of 14.42, a difference that did not reach statistical significance. This age matching matters because age is among the strongest predictors of severe COVID-19, and any meaningful gap in age distribution could have distorted the apparent effect of liver disease. Within the liver disease group, cirrhosis dominated the diagnostic landscape, accounting for 45.9 percent of cases, making advanced scarring of the liver the single most common underlying hepatic disorder among the affected patients.

The laboratory data revealed a striking biochemical signature distinguishing the liver disease cohort. Patients with chronic liver disease showed significantly higher serum levels of aspartate aminotransferase and alanine aminotransferase, the two canonical enzymes released when hepatocytes are injured, as well as elevated bilirubin, the pigment that accumulates when the liver’s processing capacity falters. Their prothrombin times were prolonged, indicating impaired synthesis of clotting factors by a struggling liver, and their blood urea nitrogen levels were elevated, a marker that can reflect dehydration, catabolic stress, or impaired renal perfusion, all common in decompensating cirrhotic patients. These differences were statistically significant at the conventional threshold of P less than 0.05, and together they paint a picture of patients whose hepatic reserve was already compromised before the viral infection added its own burden.

Clinical presentation also diverged between the groups in ways that carry practical implications for frontline physicians. Abdominal pain and confusion were reported more frequently among patients with chronic liver disease. Both symptoms are readily explicable by hepatic pathophysiology: abdominal pain can arise from portal hypertension, ascites stretching the peritoneum, or the capsular distension of an inflamed liver, while confusion in cirrhotic patients frequently signals hepatic encephalopathy, the neuropsychiatric syndrome caused when the failing liver fails to clear ammonia and other neurotoxic metabolites from the circulation. The overlap between encephalopathy and the confusion of severe COVID-19 hypoxia presents a genuine diagnostic challenge, and the study’s finding underscores that clinicians evaluating a confused COVID-19 patient with known liver disease must consider both mechanisms simultaneously.

The central result of the study concerns survival. After accounting for the comparison design, the researchers found that chronic liver disease was associated with higher odds of in-hospital mortality compared with the selected non-CLD comparison group. In other words, even against counterparts who were similar in age and free of other recorded chronic conditions, patients whose livers were chronically diseased died in the hospital at a meaningfully higher rate. This aligns with the mechanistic expectations that motivated the study in the first place. Patients with chronic liver disease are considered particularly vulnerable to COVID-19 because of immune dysregulation, chronic inflammation, and impaired metabolic function, a triad that leaves them less equipped to mount an effective antiviral response and more prone to the runaway inflammatory cascades that characterize severe disease.

The mechanistic plausibility of this vulnerability rests on well-characterized biology. The angiotensin-converting enzyme 2 receptor, which SARS-CoV-2 uses to enter cells, is expressed on cholangiocytes, the epithelial cells lining the bile ducts, providing a potential route for direct viral injury to the biliary tree and, indirectly, to hepatocytes. Beyond direct infection, the systemic inflammation of severe COVID-19, driven by elevated interleukin-6 and C-reactive protein, can precipitate decompensation in a cirrhotic liver that was already operating near its functional ceiling. The coagulopathy of COVID-19, marked by prolonged prothrombin times and elevated D-dimers in the sickest patients, compounds the baseline coagulation abnormalities of advanced liver disease, creating a convergent prothrombotic and prohemorrhagic hazard that neither condition alone would produce to the same degree.

Not every measured outcome differed between the groups, and the negative findings are themselves informative. The duration of hospitalization was statistically indistinguishable between patients with and without chronic liver disease, with a P value of 0.972, suggesting that among those who survived, the liver disease did not prolong the hospital stay in this cohort. The study also evaluated intensive care unit admission as an outcome, alongside demographic characteristics, clinical manifestations, laboratory parameters, and treatment outcomes, providing a broad clinical picture of how the two cohorts fared across the arc of their admissions. Analyses were performed using SPSS version 26, the standard statistical package for medical cohort studies of this scale.

The authors are careful to flag the boundaries of what their data can support. Because subgroup analyses according to cirrhosis status were not performed, no conclusions can be drawn from this cohort regarding the specific association between cirrhosis itself and clinical outcomes, even though cirrhosis was the most common underlying disorder among the liver disease patients. This is a meaningful limitation, since cirrhosis represents the extreme end of the chronic liver disease spectrum, and its specific contribution to COVID-19 mortality has been debated in the international literature. The single-center design at one hospital in Babol, and the modest sample size of 37 exposed patients, further counsel caution in generalizing the effect estimates to other populations and health care settings.

Nevertheless, the study’s practical message for clinicians is clear and actionable. A hospitalized COVID-19 patient with chronic liver disease should be recognized from the outset as belonging to a higher-risk category, warranting closer laboratory surveillance of transaminases, bilirubin, and coagulation parameters, a lower threshold for investigating altered mental status as possible encephalopathy, and heightened vigilance for the decompensation events, such as variceal bleeding, infection, and renal failure, that convert chronic hepatic disease into acute organ failure. The research was approved by the Ethics Committee of Babol University of Medical Sciences under code IR.MUBABOL.REC.1402.155, received no external funding, and was published open access on 6 October 2026, with the authors declaring no competing interests. As the pandemic’s legacy continues to be mapped across vulnerable populations, studies of this kind sharpen the clinical stratification tools that determine which patients need the most aggressive monitoring when SARS-CoV-2 arrives on the ward.

Subject of Research: The association between chronic liver disease and clinical outcomes, including in-hospital mortality, in patients hospitalized with COVID-19.

Article Title: Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran

Article References: Zabihi, R., Abedi, S. H., Shirafkan, H., Dehpanah, A. A., Raei, A., Zebardast, A., & Yahyapour, Y. (2026). Association of chronic liver disease with clinical outcomes and in-hospital mortality among hospitalized patients with COVID-19: a retrospective cohort study from Northern Iran. Gut Pathogens. https://doi.org/10.1186/s13099-026-00888-4

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00888-4

Keywords: COVID-19, chronic liver disease, cirrhosis, SARS-CoV-2, in-hospital mortality, clinical outcomes, retrospective cohort study, liver enzymes, hepatic encephalopathy, Iran, Gut Pathogens, coagulopathy

The research team, led by Antonio Esposito and Marcello Moccia of Federico II University of Naples, followed 34 adults with multiple sclerosis who started ofatumumab and remained on treatment for at least two years, with paired immune assessments at baseline and follow-up. Ofatumumab is administered as 20 milligram subcutaneous injections at weeks 0, 1, and 2, and monthly thereafter. Unlike intravenous anti-CD20 agents such as ocrelizumab and rituximab, ofatumumab acts primarily in the peripheral lymphatic compartment, and its distinct epitope binding and complement-dependent cytotoxicity have fueled speculation that its broader immunological footprint might differ from its intravenous cousins.

To map that footprint, the investigators used a standardized whole-blood flow-cytometry workflow. Fifty-microliter blood samples were incubated with fluorochrome-conjugated antibody mixtures, red blood cells were lysed, and the remaining nucleated cells were acquired on a Beckman Coulter Navios cytometer equipped with 405-, 488-, and 638-nanometer lasers. Sequential gating identified the major lymphocyte lineages: CD3-positive T cells and their CD4 and CD8 subsets, CD19- and CD20-positive B cells, CD56-positive natural killer cells, CD27-positive populations, memory B cells carrying both CD27 and CD19, and the small CD3-positive CD20-positive T-cell subset that anti-CD20 therapy is known to eliminate. Absolute counts were obtained using a double-platform approach under routine quality-control standards, including instrument calibration and participation in the UK-NEQAS external quality assessment scheme.

The longitudinal analysis relied on linear mixed-effects regression, with fixed effects for age, sex, follow-up duration, comorbidities, body mass index, and previous disease-modifying therapy, and a random intercept for each participant. The results were striking. Over roughly two years of treatment, total lymphocyte counts rose by an average of about 251 cells per microliter, while CD3-positive T cells increased by roughly 369, CD4-positive T cells by about 240, CD8-positive T cells by about 132, CD27-positive cells by about 275, and CD27-positive CD3-positive T cells by about 452. All of these increases were statistically significant, with confidence intervals that excluded the null. In parallel, the expected depletion was unmistakable: CD19-positive and CD20-positive B cells fell by about 182 cells per microliter, and CD27-positive CD19-positive memory B cells dropped sharply as well.

Not everything moved, however. The ratio of CD4 to CD8 T cells remained stable, as did CD56-positive natural killer cells and the CD3-positive CD20-positive T-cell subset. That stability of the CD4-to-CD8 ratio is important, because it suggests that no major rebalancing occurred between the two broad arms of the T-cell compartment, even as absolute T-cell numbers climbed. The authors are careful to note that the rise in CD27-positive cells cannot be taken as evidence of naive T-cell expansion. CD27 is expressed across both naive and central memory T-cell compartments and also appears on subsets of natural killer and natural killer T cells. Without additional differentiation markers such as CD45RA, CD45RO, and CCR7, the specific CD27-expressing population driving the increase cannot be resolved with the panel used.

What, then, explains the T-cell rise? The authors propose that the pattern may reflect broad reorganization of the T-cell compartment following sustained B-cell depletion, a phenomenon that has been hinted at in other anti-CD20 studies. Previous short-term real-world investigations of ofatumumab generally found CD3, CD4, and CD8 counts to be broadly stable, which makes the two-year increases reported here particularly noteworthy. The discrepancy may be a matter of timing: early immune kinetics differ from the intermediate and long-term reorganization that unfolds as the immune system adapts to life without circulating CD20-positive B cells. Other variables complicate the picture, including prior exposure to therapies such as natalizumab or fingolimod, which reshape peripheral immune pools and trafficking patterns, and differences in measurement approaches, such as whether studies use surface-epitope or intracellular CD20 staining, the latter avoiding steric hindrance by therapeutic antibodies still circulating in the blood.

The study also looked for clinical meaning behind these immune shifts. Using multivariable logistic regression, the team tested whether the annualized percentage change in each laboratory measure predicted relapses, magnetic resonance imaging activity, progression on the Expanded Disability Status Scale, improvement on that scale, or the composite outcome of no evidence of disease activity, known as NEDA-3. The answer, in every case, was no. No significant associations emerged between changes in any lymphocyte population and any clinical or radiological outcome. Several models could not be reliably estimated at all because clinical and MRI events were so rare, a consequence of treating patients with a highly effective therapy, and because near-complete B-cell depletion left little variability to model.

The authors are refreshingly candid about what these negative findings do and do not mean. With only 34 participants and a low frequency of disease-activity events, the study was never powered to detect subtle immunological-clinical relationships, and the absence of statistical significance should not be read as evidence that such relationships do not exist. The analyses were explicitly designed to be hypothesis-generating rather than to establish mechanistic pathways or predictive biomarkers. Most participants had prior exposure to other disease-modifying therapies, and although previous treatment was included as a covariate, residual carry-over effects on immune composition cannot be excluded. There was also no parallel comparator group receiving ocrelizumab or rituximab, which limits direct inference about how ofatumumab’s subcutaneous route and pharmacology might differ from intravenous anti-CD20 agents, and no standardized intermediate sampling at six and twelve months to reconstruct the early-to-late kinetics of immune change.

Those limitations point directly toward the next generation of experiments. The immunophenotyping panel used here captured broad lymphocyte populations but could not resolve the smaller, functionally critical subsets that other work has implicated in anti-CD20 responses, including Th17 and Th17.1 cells, T follicular helper cells, and their regulatory counterparts. Cross-sectional research during ofatumumab treatment has documented improved Th17.1-to-regulatory-T-cell and T follicular helper-to-follicular regulatory T-cell ratios, reduced pro-inflammatory cytokine production, and impaired migration of residual CD20-positive T cells across an inflamed model of the blood-brain barrier. A multicenter comparison of ocrelizumab and ofatumumab found more pronounced reductions of B and CD8-positive cells with ocrelizumab, while total lymphocytes, CD4 cells, and natural killer cells remained similar between the two drugs. Functional readouts such as cytokine profiling, migration assays, standardized immunoglobulin tracking, and assessments of vaccine responses and infection risk would round out the safety picture.

For now, the study delivers a clear and reassuring headline finding: two years of ofatumumab produces sustained, near-complete depletion of circulating CD19- and CD20-positive B cells, exactly as its mechanism of action predicts, alongside a measurable and statistically robust expansion of broad T-cell compartments that remains clinically silent, at least as far as conventional outcome measures can detect. Whether that T-cell expansion represents a benign consequence of B-cell depletion, a compensatory homeostatic response, or a subtle repositioning of the immune system toward a more anti-inflammatory profile remains an open question. Answering it will require larger prospective cohorts, repeated longitudinal sampling, deeper immunophenotyping panels, and the functional assays that can translate cell counts into biological meaning. Until then, this two-year window into the immune life of ofatumumab-treated patients stands as a valuable benchmark for what long-term B-cell depletion actually looks like in the blood of people living with multiple sclerosis.

Subject of Research: Longitudinal immune profiling of lymphocyte subsets in multiple sclerosis patients treated with the anti-CD20 antibody ofatumumab

Article Title: Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates

Article References: Esposito, A., Corsaro, L., Cave, I. D., Capasso, F., Corsini, G., Matrone, G., Cerbone, V., Petracca, M., Carotenuto, A., Lanzillo, R., Scalia, G., Castaldo, G., Morra, V. B., & Moccia, M. (2026). Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates. Journal of Neurology, 273(10), Article 579. https://doi.org/10.1007/s00415-026-14088-2

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14088-2

Keywords: multiple sclerosis, ofatumumab, anti-CD20, B-cell depletion, T cells, flow cytometry, immune profiling, lymphocytes, NEDA-3, clinical outcomes, immunotherapy, Journal of Neurology

The study, led by Ottavia Cozzi and Daijiro Tomii of Bern University Hospital together with senior author Thomas Pilgrim, categorized 732 patients according to computed tomography-derived annular area, defining a small annulus as 430 square millimeters or less. This threshold is the most widely applied cut-off in the contemporary literature, and the researchers also ran sensitivity analyses using stricter definitions of 386 and 400 square millimeters. The results held firm across all definitions. In total, 323 patients, or 44.1 percent of the cohort, had a small annulus, underscoring just how frequently this anatomy appears in clinical practice.

The demographic profile of these patients was striking. More than 84 percent of those with a small annulus were women, compared with just over a third of patients with larger annuli. Women with severe aortic stenosis often present with more advanced disease and greater frailty at the time of intervention, a pattern thought to reflect later detection and delayed referral. Patients with small annuli also carried slightly higher predicted surgical risk, with a median Society of Thoracic Surgeons Predicted Risk of Mortality score of 3.8 percent versus 3.3 percent. By contrast, atrial fibrillation, obstructive coronary artery disease, and prior cardiothoracic surgery were more common among those with larger annuli, painting two distinct clinical phenotypes.

Hemodynamically, the small-annulus group did face measurable disadvantages. Thirty days after the procedure, echocardiography revealed higher mean transprosthetic gradients of 10 millimeters of mercury compared with 8 in the larger-annulus group, and a higher prevalence of residual gradients exceeding 20 millimeters of mercury. The effective orifice area and its indexed value were both significantly smaller, translating into a higher rate of moderate or severe prosthesis-patient mismatch, a condition in which the implanted valve is too small relative to the patient’s body size to permit unimpeded blood flow. In theory, such suboptimal forward flow should reduce exercise capacity and erode quality of life.

Yet the clinical data told a different story. At three years, all-cause mortality was actually numerically lower in the small-annulus group, at 18.6 percent versus 25.4 percent, a difference that was not statistically significant after adjustment. Cardiovascular death and hospitalization for heart failure were likewise comparable between groups. The researchers went a step further by evaluating an integrated patient-centered endpoint: being alive with good health status, defined as a Kansas City Cardiomyopathy Questionnaire overall summary score of at least 75 without a decline of more than 10 points from baseline. At three years, 46.5 percent of small-annulus patients achieved this demanding benchmark, compared with 43.2 percent of those with larger annuli, an odds ratio of 0.95 that was firmly within the range of chance.

Patient-reported health status itself followed a similar trajectory in both groups. Baseline Kansas City Cardiomyopathy Questionnaire scores were nearly identical, hovering in the mid-50s, and rose sharply after valve replacement in both cohorts. Although patients with small annuli experienced a slightly smaller early improvement at 30 days, ordinal analysis showed that more than 70 percent of patients in both groups enjoyed at least mild improvement at one and three years. By the three-year mark, median overall summary scores remained in the low 80s for both groups, indicating sustained, meaningful recovery in symptoms, physical limitation, and quality of life after the procedure.

The most provocative finding emerged from an exploratory factorial analysis examining the interplay between annular size and valve type. The SCOPE I trial had randomized patients to either the self-expanding ACURATE Neo from Boston Scientific or the balloon-expandable SAPIEN 3 from Edwards Lifesciences. When the investigators crossed annular size with valve type, a statistically significant interaction appeared for the patient-centered outcome. Patients with a small annulus treated with the balloon-expandable SAPIEN 3 had a lower probability of being alive with good health status at three years, with a relative risk of 0.59 and a p-value for interaction of 0.004. No such difference between valve types was seen in patients with larger annuli.

The mechanism behind this interaction remains speculative. The authors note that the intra-annular leaflet position of the balloon-expandable platform, together with differences in skirt design, frame expansion within a constrained annulus, and commissural alignment, may yield less favorable forward hemodynamics than a supra-annular design. They also point to the randomized SMART trial, which compared the SAPIEN 3 with the supra-annular Evolut valve specifically in small-annulus patients and found better echocardiographic valve performance and more frequent health-status improvement with the self-expanding device, though without differences in hard clinical endpoints. The researchers caution that echocardiography may systematically favor supra-annular devices due to measurement methodology, and that the apparent hemodynamic superiority should not be equated with definitive clinical advantage.

Several caveats temper the conclusions. As a post-hoc analysis, the study was not powered to detect differences by annular size, and all interaction analyses are exploratory. Residual imbalances persisted in sex, left ventricular ejection fraction, and serum creatinine even after propensity-based overlap weighting. Questionnaire data were available only for survivors who completed follow-up, and objective exercise testing was not systematically collected, leaving open the possibility of subtle functional differences. The advanced age of the cohort, with a median of 83 years, may also have blunted the functional impact of suboptimal hemodynamics, and the findings may not extend to younger, more active patients treated at lower surgical risk.

Practical implications nonetheless emerge. A small aortic annulus, present in more than 40 percent of TAVR candidates and overwhelmingly among women, should not be regarded as a barrier to excellent outcomes. The hemodynamic penalties visible on echocardiography do not translate into worse survival or diminished quality-of-life recovery over three years in well-selected patients. At the same time, the valve-type interaction hints that device selection may matter more in this anatomy than previously appreciated, a hypothesis that will require confirmation in adequately powered studies with contemporary devices, particularly as the ACURATE platform has since been withdrawn from clinical use and newer iterations of balloon-expandable valves have shown improved hemodynamics in smaller sizes. For now, the message to patients and physicians alike is one of cautious reassurance.

Subject of Research: Impact of small aortic annulus size on clinical and quality-of-life outcomes after transcatheter aortic valve replacement

Article Title: Relationship between a small aortic annulus and clinical and quality-of-life outcomes in patients undergoing TAVR

Article References: Cozzi, O., Tomii, D., Lanz, J., Heg, D., Thiele, H., Kim, W.-K., Joner, M., Thilo, C., Toggweiler, S., Prendergast, B., Windecker, S., Pilgrim, T., & the SCOPE I Investigators (2026). Relationship between a small aortic annulus and clinical and quality-of-life outcomes in patients undergoing TAVR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03025-y

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03025-y

Keywords: TAVR, aortic stenosis, small aortic annulus, prosthesis-patient mismatch, Kansas City Cardiomyopathy Questionnaire, transcatheter heart valve, SCOPE I trial, patient-reported outcomes, valve hemodynamics, cardiology, heart valve replacement, clinical outcomes

The significance of the question is difficult to overstate. Diagnostic labels in psychiatry are not merely administrative conveniences; they shape treatment decisions, prognosis conversations, eligibility for services, disability determinations, and the direction of a patient’s entire clinical trajectory. When a young person presents with hallucinations, delusions, disorganized thinking, or negative symptoms for the first time, clinicians face acute pressure to classify the presentation quickly. The Diagnostic and Statistical Manual of Mental Disorders, in its fifth edition, formalized the other specified schizophrenia spectrum and other psychotic disorder category precisely to accommodate presentations that are clinically significant but fall short of complete diagnostic thresholds, whether because symptom duration, symptom count, or functional decline criteria are not fully met. In practice, this category has often been treated clinically as a probable precursor to schizophrenia, a kind of pre-diagnosis that carries an implicit expectation of progression.

That expectation, the new research suggests, may be systematically wrong. By following individuals who received a first-episode diagnosis within the other specified category and tracking both their diagnostic course and their functional and symptomatic outcomes over time, the investigators assembled a longitudinal picture of what actually happens to this population. If the category were merely an early stage of schizophrenia, one would expect the majority of cases to convert to a full schizophrenia diagnosis as symptoms consolidate and duration criteria are eventually satisfied. If the category instead captured a heterogeneous mix of transient, attenuated, or genuinely atypical psychotic experiences, one would expect substantial migration in multiple directions, with many patients improving, some shifting to other spectrum diagnoses, and a minority remaining stably within the unspecified label. The study’s findings, summarized in its title as evidence for a distinct clinical entity, point toward the latter pattern, with a profile of outcomes that does not simply recapitulate the natural history of first-episode schizophrenia.

From a methodological standpoint, the study addresses one of the most persistent weaknesses in psychosis research: the tendency to exclude or lump together patients who do not fit clean diagnostic categories. Large longitudinal cohorts of first-episode psychosis frequently stratify participants by diagnosis, comparing schizophrenia, schizoaffective disorder, affective psychosis with psychotic features, and brief psychotic disorder. Patients carrying other specified diagnoses are often either folded into a residual group or dropped from analyses altogether, a practice that both inflates the apparent homogeneity of named categories and renders the most diagnostically uncertain patients invisible to science. By placing this group at the center of inquiry rather than the margin, the study recovers a population that is common in real-world clinical settings, particularly in early intervention services where careful, provisional first diagnoses are the norm.

The clinical implications of diagnostic stability data are immediate and practical. When clinicians can tell a patient and family that a given first-episode diagnosis carries a known probability of remaining stable, of resolving, or of evolving into another condition, the conversation changes from one of vague reassurance to one of quantified expectation. For the other specified category, the traditional assumption of inevitable progression toward schizophrenia has arguably generated unwarranted pessimism, potentially influencing clinicians and families to interpret ambiguous developments through the darkest available lens. A more accurate empirical picture, in which many individuals with this diagnosis do not progress to schizophrenia and may show outcomes better than typically reported for first-episode schizophrenia itself, could recalibrate prognostic communication, reduce stigma associated with the initial diagnosis, and encourage appropriately intensive but not fatalistic monitoring.

The study also speaks to a deeper theoretical tension in psychiatric nosology. Since the reliability-focused reforms of DSM-III in 1980, diagnostic categories in psychiatry have been treated as if they carve nature at its joints, yet decades of research on symptom dimensions, genetic correlations, and transdiagnostic mechanisms have repeatedly suggested that psychosis exists on continua rather than in discrete boxes. The other specified category occupies an awkward position in this debate. Critics have argued that such residual categories are nosological dustbins that undermine the validity of the system by concealing heterogeneity. Proponents counter that they honestly reflect the limits of current diagnostic science while preserving clinical flexibility. Evidence that a residual category shows internal coherence, in the form of reasonably stable diagnoses and a characteristic outcome profile, would challenge the dustbin interpretation and lend support to the possibility that some presentations currently labeled as other specified represent a genuinely identifiable syndrome that current criteria simply lack the vocabulary to name.

The distinction matters enormously for early intervention research and service design. Early intervention in psychosis programs, which have proliferated internationally and demonstrated meaningful benefits for functional recovery, typically enroll patients within a defined window after the first psychotic episode and tailor treatment intensity to expected risk. If a substantial fraction of patients carrying provisional unspecified diagnoses actually have a milder or more remitting condition, blanket application of protocols designed for schizophrenia may represent both an inefficient allocation of intensive resources and an iatrogenic risk, exposing individuals to antipsychotic treatment durations and prognostic messaging calibrated to a more severe illness than the one they have. Conversely, if a meaningful subset of these patients does deteriorate, identifying reliable early predictors of that trajectory becomes a priority. Longitudinal outcome data of the kind reported in this study provide the empirical foundation on which such stratified approaches must be built, because risk prediction is only as good as the outcome distributions it is trained to anticipate.

The findings also carry weight for the ongoing revision debates surrounding psychiatric classification. The research community preparing future editions of the DSM and the International Classification of Diseases has grappled with proposals ranging from dimensional severity ratings to wholesale reorganization of the psychosis section. Any proposal to promote, split, merge, or retire diagnostic categories ultimately depends on longitudinal evidence about stability, outcomes, and treatment response. A demonstration that the other specified schizophrenia spectrum category functions as a distinct clinical entity, rather than as an early or attenuated form of schizophrenia, would argue for either a named and criterion-defined diagnosis in future classifications or, at minimum, explicit guidance distinguishing it from the prodromal and precursor states with which it is often conflated. Classification follows evidence, and evidence of this kind is precisely what has been missing.

As with any single study, the new findings invite replication across independent cohorts, diverse health systems, and longer follow-up horizons, and they raise the familiar interpretive challenges of observational psychiatric research, including the influence of treatment on observed trajectories and the possibility that referral patterns shape who receives the unspecified label in the first place. Yet the core contribution stands on its own terms. A diagnosis long treated as an administrative compromise, a reluctant concession to diagnostic uncertainty, has been subjected to the same longitudinal scrutiny applied to schizophrenia itself and has emerged with a recognizable clinical identity. For the many patients who carry this label during the most disorienting period of their lives, and for the clinicians and families navigating that period alongside them, the message is a quietly radical one: an unspecified diagnosis is not a disguised certainty of schizophrenia, and the natural history of this condition deserves to be understood, studied, and treated on its own evidence.

Subject of Research: Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder

Article Title: Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder: evidence for a distinct clinical entity

Article References: Setiani, A., Li, L., Odkhuu, S., Kim, W.-S., Nazir, S., Starzer, M. S. K., Weibell, M., Chen, E. Y. H., Liu, C.-C., Mizuno, M., & Chung, Y.-C. (2026). Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder: evidence for a distinct clinical entity. Schizophrenia. https://doi.org/10.1038/s41537-026-00804-4

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00804-4

Keywords: schizophrenia spectrum, first-episode psychosis, diagnostic stability, DSM-5, psychiatric nosology, early intervention, clinical outcomes, psychotic disorders, prognosis, longitudinal study, Clinical, outcomes